[1] GIOVANNI LEONE Alessia P. Profile of clinical efficacy and safety of topical tacalcitol.[J]. Acta Biomedica de l”Ateneo Parmense, 2005, 76 1: 13-19.
[2] FRANCESCA PRIGNANO Torello L Gionata Buggiani. Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patients.[J]. Acta Biomedica de l”Ateneo Parmense, 2009, 80 1: 51-56.
[3] KUNIO MATSUMOTO. Effect of 1,24R-dihydroxyvitamin D3 on the Growth of Human Keratinocytes[J]. Journal of Dermatology, 1990, 17 2: 97-103. DOI:
10.1111/j.1346-8138.1990.tb03714.x[4] MASAMI FUKUOKA. Regulation of RANTES and IL-8 production in normal human dermal fibroblasts by active vitamin D3 (tacalcitol)[J]. British Journal of Pharmacology, 2009, 124 7: 1433-1438. DOI:
10.1038/sj.bjp.0701988[5] K.-I. YAMANAKA. 1,24-Dihydroxyvitamin D3 (tacalcitol) prevents skin T-cell infiltration[J]. British Journal of Dermatology, 2010, 162 6: 1206-1215. DOI:
10.1111/j.1365-2133.2010.09692.x